ReviewMolecules (Basel, Switzerland)2015
68Ga-Based radiopharmaceuticals: production and application relationship.
Review in Molecules (Basel, Switzerland), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05165602 (Evaluation of HER2-targeted Therapy for Gastric Cancer and Establishment and Verification of Monitoring System), which is not on this map. Cited by 105 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of HER2-targeted Therapy for Gastric Cancer and Establishment and Verification of Monitoring System
Who cites it
105 citing papers in PubMed, 1 synthesis or guideline pooled it, 248 citations in OpenAlex.
- Comparative diagnostic performance of [68 Ga]Ga-FAPI PET/CT and [18 F]FDGPET/CT in biliary tract cancers: a systematic review and meta-analysis.European journal of nuclear medicine and molecular imaging · 2025Pooled it
- A Randomized, Factorial Phase II Study to Determine the Optimal Dosing Regimen forJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Trial
- Convenient Preparation of [(68)Ga]DKFZ-PSMA-11 Using a Robust Single-Vial Kit and Demonstration of Its Clinical Efficacy.Molecular imaging and biology · 2016Trial
- Biodistribution, dosimetry, and temporal signal-to-noise ratio analyses of normal and cancer uptake of [Nuclear medicine and biologyTrial
- Dynamic coordination engineering of gallium biomaterials: A biological accessibility framework for therapeutic biofunction.Bioactive materials · 2027Review
- Repurposing radiopharmaceutical carriers for targeted drug delivery and theranostics: A translational framework.Pharmaceutical science advances · 2026Review
- Development and preclinical evaluation of selective vinyl sulfone-based probes for PET imaging of tumor-associated cathepsins.EJNMMI radiopharmacy and chemistry · 2026Article
- [Chemical & biomedical imaging · 2026Article
- Automated Synthesis of Radiopharmaceuticals: Technology, Applications, and Regulatory Perspectives.Nuclear medicine and molecular imaging · 2026Review
- Development of an automated radiosynthesis for [EJNMMI radiopharmacy and chemistry · 2026Article
- TheEJNMMI radiopharmacy and chemistry · 2026Article
- Long-term performance evaluation of a novel 3.26 GBqEJNMMI radiopharmacy and chemistry · 2026Article
- Increasing the activity output and optimization of automated radiosynthesis [EJNMMI radiopharmacy and chemistry · 2026Article
- Advancements in Targeted Radiopharmaceuticals: Innovations in Diagnosis and Therapy for Enhanced Cancer Management.Chembiochem : a European journal of chemical biology · 2026Review
- Design and Preclinical Evaluation of FirstJournal of medicinal chemistry · 2025Article
- Ga-68-Labeled Affibody Molecule-Based Radiopharmaceutical Targeting Platelet Derived Growth Factor Receptor Beta for Detection of Active Fibrosis in Patients with Myocardial Infarction.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Production and Quality Control of [Pharmaceuticals (Basel, Switzerland) · 2025Article
- Theranostics in nuclear medicine: the era of precision oncology.Medical oncology (Northwood, London, England) · 2025Review
- Thwarting Isomerization through Rigidity: A Promising HBED Derivative for the Chelation of Gallium-68.Inorganic chemistry · 2025Article
- Optimized Automated Cassette-Based Synthesis of [Pharmaceuticals (Basel, Switzerland) · 2025Article
45 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The contribution of 68Ga to the promotion and expansion of clinical research and routine positron emission tomography (PET) for earlier better diagnostics and individualized medicine is considerable. The potential applications of 68Ga-comprising imaging agents include targeted, pre-targeted and non-targeted imaging. This review discusses the key aspects of the production of 68Ga and 68Ga-based radiopharmaceuticals in the light of the impact of regulatory requirements and endpoint pre-clinical and clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.